Biomarker Testing and HER2-Mutant NSCLC

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, emphasize the critical role of comprehensive biomarker testing in identifying HER2-mutant non–small cell lung cancer. Dietrich highlights the importance of incorporating broad next-generation sequencing panels to distinguish HER2 mutations from amplification or overexpression. Leal underscores that early and accurate molecular identification is essential for guiding optimal frontline treatment strategies and ensuring appropriate use of targeted therapies.